FDA’s Advisory Committee Approves Actavis (ACT) Anti-Biotic

December 6, 2014 6:51 PM

2 0

FDA’s Advisory Committee Approves Actavis (ACT) Anti-Biotic

Recently, Actavis plc (Nyse:act) declared that its trail anti-biotic, ceftazidime-avibactam, has been prescribed by the US Food & Drug Administration’s (FDA) Anti-Infective Drugs Advisory Committee, for treating intricate intra-abdominal diseases (cIAI) and convoluted urinary tract diseases (cUTI) brought on by drug resistant bacteria.

Actavis is co-creating the medication with Astrazeneca plc (ADR) (Nyse:azn). According to the terms of the agreement, Actavis possesses the privileges of the medication in North America, though Astrazeneca holds the rights for it in other nations.

Read more

To category page

Loading...